Copy to clipboard 
Bio-Gate AG announced that it concluded a contract with a leading multinational medical device manufacturer for the coating of orthopedic implants. As part of the cooperation and the joint project management, Bio-Gate is responsible for the application engineering and production of the HyProtect coating, and will also support the regulatory pathway for the implants.
“The recently concluded contract is another important step for us to successively expand the medical technology business field into another growth driver in the Bio-Gate Group,” said Marc Lloret-Grau, CEO, Bio-Gate. “Now that we have already concluded the second important cooperation agreement with a multinational medical device provider, we also want to push ahead with talks with implant manufacturers in the USA.”
Scientific publications have shown that Bio-Gate’s HyProtect antimicrobial coating technology is able to kill multi-resistant germs. Since 2013, more than 110 people worldwide (in Germany, Switzerland, Australia, New Zealand, the UK and the US) have successfully received HyProtect-coated implants in the form of custom implants and compassionate care cases (healing trials). So far, four scientific publications on individual cases have been published.
The existing database on the HyProtect technology, as well as the successful outcome of the single patient cases in particularly at-risk patients, are key elements for the cooperation agreement with the multinational implant manufacturer. The customer, together with Bio-Gate, is in the process of preparing the regulatory clearance documents. Progress is already being made on the regulatory side. In addition to the remuneration for the project management and coatings, Bio-Gate will also receive license payments once the implants have been launched on the market.
